Primecap Management Co. CA Has $2.01 Million Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Key Points

• Primecap Management Co. CA reduced its holdings in Zentalis Pharmaceuticals by 16.8%, owning 1,264,620 shares worth $2,011,000 as of the latest SEC filing.
• Zentalis Pharmaceuticals reported earnings per share (EPS) of ($0.37) for the last quarter, beating expectations of ($0.56) by $0.19.
• Analysts have set a consensus target price of $8.20 for Zentalis stock, with various ratings ranging from "neutral" to "buy" from different firms.

Primecap Management Co. CA lowered its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 16.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,264,620 shares of the company's stock after selling 256,010 shares during the period. Primecap Management Co. CA owned 1.76% of Zentalis Pharmaceuticals worth $2,011,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Deutsche Bank AG raised its stake in shares of Zentalis Pharmaceuticals by 34.1% in the fourth quarter. Deutsche Bank AG now owns 42,804 shares of the company's stock valued at $130,000 after acquiring an additional 10,873 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in shares of Zentalis Pharmaceuticals by 17.0% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 234,071 shares of the company's stock valued at $372,000 after acquiring an additional 33,958 shares during the last quarter. BNP Paribas Financial Markets bought a new position in shares of Zentalis Pharmaceuticals in the fourth quarter valued at approximately $534,000. Millennium Management LLC raised its stake in shares of Zentalis Pharmaceuticals by 8.1% in the fourth quarter. Millennium Management LLC now owns 957,563 shares of the company's stock valued at $2,901,000 after acquiring an additional 71,477 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its stake in shares of Zentalis Pharmaceuticals by 169.2% in the fourth quarter. Russell Investments Group Ltd. now owns 60,021 shares of the company's stock valued at $182,000 after acquiring an additional 37,726 shares during the last quarter.

Zentalis Pharmaceuticals Stock Performance

ZNTL stock traded down $0.01 during midday trading on Tuesday, hitting $1.40. 188,940 shares of the company's stock were exchanged, compared to its average volume of 1,239,485. The stock's fifty day moving average price is $1.38 and its 200-day moving average price is $1.55. The company has a market cap of $100.64 million, a PE ratio of -0.62 and a beta of 1.71. Zentalis Pharmaceuticals, Inc. has a one year low of $1.01 and a one year high of $5.44.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.19. On average, analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Analysts Set New Price Targets

ZNTL has been the subject of several research analyst reports. HC Wainwright upgraded shares of Zentalis Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, August 7th. Wall Street Zen upgraded shares of Zentalis Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Saturday. Wells Fargo & Company dropped their price objective on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an "equal weight" rating for the company in a research report on Thursday, August 7th. Finally, Wedbush restated a "neutral" rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Thursday, May 15th. Four analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $8.20.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.